These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38712939)

  • 1. Predicting response to neoadjuvant chemotherapy for colorectal liver metastasis using deep learning on prechemotherapy cross-sectional imaging.
    Davis JMK; Niazi MKK; Ricker AB; Tavolara TE; Robinson JN; Annanurov B; Smith K; Mantha R; Hwang J; Shrestha R; Iannitti DA; Martinie JB; Baker EH; Gurcan MN; Vrochides D
    J Surg Oncol; 2024 Jul; 130(1):93-101. PubMed ID: 38712939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
    Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
    Takatsuki M; Tokunaga S; Uchida S; Sakoda M; Shirabe K; Beppu T; Emi Y; Oki E; Ueno S; Eguchi S; Akagi Y; Ogata Y; Baba H; Natsugoe S; Maehara Y;
    Eur J Surg Oncol; 2016 Feb; 42(2):184-9. PubMed ID: 26683263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT-based radiomics for the identification of colorectal cancer liver metastases sensitive to first-line irinotecan-based chemotherapy.
    Qi W; Yang J; Zheng L; Lu Y; Liu R; Ju Y; Niu T; Wang D
    Med Phys; 2023 May; 50(5):2705-2714. PubMed ID: 36841949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases.
    Wei J; Cheng J; Gu D; Chai F; Hong N; Wang Y; Tian J
    Med Phys; 2021 Jan; 48(1):513-522. PubMed ID: 33119899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.
    Li ZY; Wang XD; Li M; Liu XJ; Ye Z; Song B; Yuan F; Yuan Y; Xia CC; Zhang X; Li Q
    World J Gastroenterol; 2020 May; 26(19):2388-2402. PubMed ID: 32476800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological response of colorectal liver metastases treated after induction treatment.
    Ben Slama S; Bacha D; Sassi A; Khadhar A; Bayar R; Bouraoui S; Lahmar A
    Tunis Med; 2017 Oct; 95(10):854-858. PubMed ID: 29873054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
    Lubezky N; Geva R; Shmueli E; Nakache R; Klausner JM; Figer A; Ben-Haim M
    World J Surg; 2009 May; 33(5):1028-34. PubMed ID: 19234865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Rubbia-Brandt L; Giostra E; Brezault C; Roth AD; Andres A; Audard V; Sartoretti P; Dousset B; Majno PE; Soubrane O; Chaussade S; Mentha G; Terris B
    Ann Oncol; 2007 Feb; 18(2):299-304. PubMed ID: 17060484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
    Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
    Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
    Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
    Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
    Alberts S; Poston G
    Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
    Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
    J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.